Table 3 Baseline characteristics of EOCAD patients who underwent PCI stratified by tertiles of TyG index
|  | Overall N = 1302 | Tertile 1 N = 435 | Tertile 2 N = 433 | Tertile 3 N = 434 | p-value |
|---|---|---|---|---|---|
General conditions | |||||
 Age, year | 39.5 ± 4.5 | 39.7 ± 4.5 | 39.3 ± 4.5 | 39.5 ± 4.4 | 0.43 |
 Female, n (%) | 54 (4.1) | 32 (7.4) | 14 (3.2) | 8 (1.8) |  < 0.001 |
 BMI, kg/m2 | 26.5 ± 3.5 | 25.6 ± 3.4 | 26.8 ± 3.4 | 27.2 ± 3.6 |  < 0.001 |
Body type, n (%) |  |  |  |  |  < 0.001 |
 Normal | 285 (22.4) | 137 (32.5) | 76 (18.0) | 72 (16.9) |  |
 Overweight | 598 (47.0) | 194 (46.1) | 212 (50.1) | 192 (45.0) |  |
 Obesity | 388 (30.5) | 90 (21.4) | 135 (31.9) | 163 (38.2) |  |
 Heart rate | 77.9 ± 13.0 | 76.2 ± 12.9 | 78.2 ± 12.9 | 79.3 ± 13.1 | 0.001 |
 SBP, mmHg | 128.0 ± 18.9 | 126.0 ± 17.7 | 127.2 ± 18.6 | 130.9 ± 19.9 |  < 0.001 |
 DBP, mmHg | 81.2 ± 13.8 | 80.0 ± 13.0 | 80.3 ± 13.3 | 83.3 ± 14.8 |  < 0.001 |
Smoking, n (%) |  |  |  |  |  < 0.001 |
 Never | 321 (24.7) | 142 (32.6) | 93 (21.5) | 86 (19.8) |  |
 Former | 270 (20.7) | 91 (20.9) | 94 (21.7) | 85 (19.6) |  |
 Current | 711 (54.6) | 202 (46.4) | 246 (56.8) | 263 (60.6) |  |
 Drinking, n (%) | 564 (43.3) | 149 (34.3) | 215 (49.7) | 200 (46.1) |  < 0.001 |
Comorbidities, n (%) | |||||
 Hypertension | 566 (43.5) | 176 (40.5) | 176 (40.6) | 214 (49.3) | 0.01 |
 DM | 325 (25.0) | 66 (15.2) | 78 (18.0) | 181 (41.7) |  < 0.001 |
 Dyslipidemia | 763 (58.6) | 121 (27.8) | 302 (69.7) | 340 (78.3) |  < 0.001 |
 Chronic kidney disease | 31 (2.4) | 10 (2.3) | 6 (1.4) | 15 (3.5) | 0.13 |
 History of previous MI | 243 (18.7) | 88 (20.2) | 76 (17.6) | 79 (18.2) | 0.57 |
Laboratory results | |||||
 TC, mmol/l | 4.4 ± 1.5 | 3.9 ± 1.4 | 4.5 ± 1.5 | 4.7 ± 1.6 |  < 0.001 |
 TG, mmol/l | 2.4 ± 1.7 | 1.1 ± 0.3 | 2.1 ± 0.6 | 3.9 ± 1.9 |  < 0.001 |
 HDL-C, mmol/l | 1.0 ± 0.5 | 1.2 ± 0.6 | 0.9 ± 0.3 | 0.9 ± 0.4 |  < 0.001 |
 LDL-C, mmol/l | 2.7 ± 1.5 | 2.6 ± 1.7 | 2.7 ± 1.3 | 2.6 ± 1.4 | 0.36 |
 Non-HDL-C, mmol/l | 3.4 ± 1.5 | 2.8 ± 1.3 | 3.6 ± 1.4 | 3.9 ± 1.5 |  < 0.001 |
 UA, mg/dl | 6.5 ± 1.7 | 6.4 ± 1.6 | 6.6 ± 1.6 | 6.4 ± 1.7 | 0.10 |
 Scre, mg/dl | 0.9 ± 0.2 | 0.9 ± 0.2 | 0.9 ± 0.2 | 0.9 ± 0.3 | 0.69 |
 eGFR, mL/min/1.73 m2 | 92.3 [82.9–103.7] | 92.3 [82.9–102.0] | 91.8 [82.1–103.2] | 93.4 [83.7–104.7] | 0.33 |
 HbA1c, % | 6.2 ± 1.7 | 5.8 ± 1.6 | 6.1 ± 1.5 | 6.7 ± 1.9 |  < 0.001 |
 FBG, mg/dl | 6.6 ± 2.7 | 5.4 ± 1.1 | 6.0 ± 1.8 | 8.5 ± 3.6 |  < 0.001 |
Cardiovascular medications, n (%) | |||||
 Aspirin | 1127 (86.6) | 342 (78.6) | 398 (91.9) | 387 (89.2) |  < 0.001 |
 P2Y12 inhibitors | 1113 (85.5) | 338 (77.7) | 395 (91.2) | 380 (87.6) |  < 0.001 |
 Statins | 1082 (83.1) | 320 (73.6) | 385 (88.9) | 377 (86.9) |  < 0.001 |
 ACEI/ARB | 738 (56.7) | 217 (49.9) | 264 (61.0) | 257 (59.2) | 0.002 |
 β-blocker | 970 (74.5) | 292 (67.1) | 349 (80.6) | 329 (75.8) |  < 0.001 |
Angiographic findings, n (%) | |||||
 LM lesion | 58 (4.5) | 22 (5.1) | 22 (5.1) | 14 (3.2) | 0.31 |
 LAD lesion | 970 (74.5) | 317 (72.9) | 330 (76.2) | 323 (74.4) | 0.52 |
 LCX lesion | 632 (48.5) | 189 (43.4) | 228 (52.7) | 215 (49.5) | 0.02 |
 RAD lesion | 698 (53.6) | 211 (48.5) | 229 (52.9) | 258 (59.4) | 0.005 |
 Multivessel lesion | 754 (57.9) | 229 (52.6) | 259 (59.8) | 266 (61.3) | 0.02 |
Diagnosis, n (%) | Â | Â | Â | Â | 0.07 |
 AMI | 630 (48.4) | 193 (44.4) | 214 (49.4) | 223 (51.4) |  |
 Stable angina | 461 (35.4) | 173 (39.8) | 139 (32.1) | 149 (34.3) |  |
 Unstable angina | 211 (16.2) | 69 (15.9) | 80 (18.5) | 62 (14.3) |  |
 Gensini score | 49.0 [32.0–82.0] | 47.0 [31.8–80.0] | 49.0 [32.0–82.0] | 52.5 [32.0–82.0] | 0.32 |
 LVEF, % | 58.2 ± 9.3 | 58.3 ± 9.4 | 58.4 ± 9.1 | 58.0 ± 9.4 | 0.80 |
Types of PCI, n (%) | Â | Â | Â | Â | 0.23 |
 DES | 1211 (93.0) | 405 (93.1) | 409 (94.5) | 397 (91.5) |  |
 DEB/PTCA | 91 (7.0) | 30 (6.9) | 24 (5.5) | 37 (8.5) |  |
 Follow-up time, months | 33 (31–34) | 33 (31–34) | 32 (31–34) | 33 (31–35) | 0.39 |
 Target lesion failure, n (%) | 43 (3.3) | 10 (2.3) | 16 (3.7) | 17 (3.9) |  < 0.001 |